ASCO Renal Cell Carcinoma

Scott Tykodi, MD, PhD, on Takeaways from KEYNOTE-427 in Renal Cell Carcinoma
July 24, 2020

The Seattle Cancer Care Alliance expert discusses key takeaways from cohort a of the KEYTRUDA-427 study, evaluating pembrolizumab monotherapy in patients with clear cell renal cell carcinoma.

Scott Tykodi, MD, PhD, Discusses Biomarker Detection, Analysis in RCC
July 13, 2020

The Seattle Cancer Care Alliance Expert offered background on cohort A of the KEYNOTE-427 trial.

Elizabeth Plimack, MD, MS, on Depth of Response in from the KEYNOTE-426 Trial
June 28, 2020

Elizabeth Plimack, MD, MS, discussed the depth of response for patients included in the KEYNOTE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.